Parkinson disease

@article{Poewe2017ParkinsonD,
  title={Parkinson disease},
  author={Werner Poewe and Klaus Seppi and Caroline M. Tanner and Glenda M. Halliday and Patrik Brundin and Jens Volkmann and Anette E Schrag and Anthony E. Lang},
  journal={Nature Reviews Disease Primers},
  year={2017},
  volume={3}
}
Parkinson disease is the second-most common neurodegenerative disorder that affects 2–3% of the population ≥65 years of age. Neuronal loss in the substantia nigra, which causes striatal dopamine deficiency, and intracellular inclusions containing aggregates of α-synuclein are the neuropathological hallmarks of Parkinson disease. Multiple other cell types throughout the central and peripheral autonomic nervous system are also involved, probably from early disease onwards. Although clinical… Expand

Paper Mentions

Observational Clinical Trial
The purpose of this study is to evaluate how safinamide, rasagiline and other SoC drugs are associated with the quality of life of PD patients by means of the Parkinson's Disease… Expand
ConditionsParkinson's Disease
Interventional Clinical Trial
Parkinson's disease (PD) is the second most important neurodegenerative disease that affects about 2% of the population over 60 years of age. About 40% of the Mexican population with PD… Expand
ConditionsParkinson Disease
InterventionDrug
Evidence for dopaminergic axonal degeneration as an early pathological process in Parkinson's disease.
TLDR
Recent evidence for early midbrain dopaminergic axonal degeneration in patients with Parkinson's disease is reviewed, and the potential role of α-synuclein accumulation in this process is explored, with a focus on studies in human populations at the imaging, post-mortem, cellular and molecular levels. Expand
Parkinson's Disease: A Review about Pathogenesis, Treatment and Experimental Models
TLDR
The primary drug for PD treatment is L-dopa; however, drug-induced dyskinesia and motor complications restricted its use as long term treatment, and dopamine agonists are alternative options for initial treatment of PD and have been reported to retard the onset of motor complications. Expand
Parkinson’s disease: etiopathogenesis and treatment
TLDR
The involvement of dopaminergic as well as noradrenergic, glutamatergic, serotonergic and adenosine pathways provide insights into the rich and variable clinical phenomenology associated with PD and the possibility of alternative therapeutic approaches beyond traditional dopamine replacement therapies. Expand
Developmental deficits and early signs of neurodegeneration revealed by PD patient derived dopamine neurons.
TLDR
A cell density-dependent method for preparing functional hiPSC-derived dopamine neurons (iDAs) with ~90% purity (TH-positive cells) is described, which can obtain high quality iDAs, which are critical for disease modeling, drug development and cell replacement therapy. Expand
Inflammation and Parkinson's disease pathogenesis: Mechanisms and therapeutic insight.
TLDR
It is demonstrated that peripheral inflammation can amplify the neuronal dysfunction induced by α-synuclein oligomers and the neuropathological consequences observed in a Parkinson's disease model, which might indicate a more specific anti- inflammation strategy rather than the generic anti-inflammatory treatment. Expand
Correlations of Neuropsychological and Metabolic Brain Changes in Parkinson's Disease and Other α-Synucleinopathies
TLDR
Advances in the statistical analysis of FDG-PET images enabling a network analysis broadened the understanding of neurodegenerative brain processes and a specific cognitive pattern related to PD was identified by applying voxel-based network modeling approach. Expand
The Role of Intermittent Fasting in Parkinson's Disease
TLDR
This viewpoint seeks to describe the putative pathophysiologic relationships amongmitochondria, alpha-synuclein and PD risk genes and to provide a background for the rationale or the use of IF and similar mitochondrial-targeting therapies in PD. Expand
The Renin–Angiotensin System Modulates Dopaminergic Neurotransmission: A New Player on the Scene
TLDR
Dopamine depletion, as in PD, increases angiotensin II expression, which stimulates or inhibits dopamine synthesis and is released via AT1 or AT2 receptors, which may have an important modulating role in the flow of information from the brain cortex to the basal ganglia. Expand
Stem Cell-Based Therapies for Parkinson Disease
TLDR
Current understanding of the molecular pathogenesis of neurodegeneration in PD is summarized and the development of new therapeutic strategies that have led to the initiation of exploratory clinical trials are discussed, focusing on the applications of stem cells for the treatment of PD. Expand
Hypothalamic α-synuclein and its relation to autonomic symptoms and neuroendocrine abnormalities in Parkinson disease.
TLDR
Future neuropathologic research using histological and functional assessments should establish the potential role of hypothalamic dysfunction on clinical burden, symptomatic therapies, and disease biomarkers in PD. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 315 REFERENCES
Pathogenic mutations in Parkinson disease
TLDR
It is suggested that deficits in mitochondrial function, oxidative and nitrosative stress, the accumulation of aberrant or misfolded proteins, and ubiquitin‐proteasome system (UPS) dysfunction may represent the principal molecular pathways that commonly underlie the pathogenesis of Parkinson disease. Expand
Monoamine Oxidase B Inhibitors for the Treatment of Parkinson’s Disease
TLDR
There is considerable laboratory evidence that MAO-B inhibitors do exert some neuroprotective properties, at least in the Parkinson’s disease models currently available, however, these models have significant limitations and caution is required in assuming that such results may easily be extrapolated to clinical trials. Expand
Genetic contributions to Parkinson's disease
TLDR
The identification of multiple genes predisposing to Parkinson's disease will assist in determining the cellular pathway/s leading to the neurodegeneration observed in this disease. Expand
Imaging insights into basal ganglia function, Parkinson's disease, and dystonia
TLDR
Functional imaging is increasingly used to assess underlying pathological processes such as neuroinflammation and abnormal protein deposition, and PET and MRI imaging is another promising approach to assess the effects of treatments designed to slow disease progression. Expand
Calcium and Parkinson's disease.
TLDR
An ongoing, NIH sponsored, Phase 3 clinical trial in North America is testing the ability of one member of the dihydropyridine class (isradipine) to slow PD progression in early stage patients, and the review summarizes the rationale for the trial and outlines some unanswered questions. Expand
Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons
TLDR
It is demonstrated that respiratory chain dysfunction in DA neurons may be of pathophysiological importance in PD and reduced mtDNA expression and respiratory chain deficiency in midbrain DA neurons leads to a parkinsonism phenotype. Expand
The Concept of Prodromal Parkinson’s Disease
TLDR
A key challenge in PD research is to identify and validate markers for the preclinical and prodromal stages of the illness, and several nonmotor symptoms have been associated with an increased risk to develop PD in otherwise healthy individuals. Expand
Neuroimaging in Parkinson disease: from research setting to clinical practice
TLDR
The lessons learnt from decades of neuroimaging research in PD are discussed, and the promising new approaches with potential applicability to clinical practice are discussed. Expand
Neuroinflammation in Parkinson's disease: a target for neuroprotection?
TLDR
Overall, available data support the importance of non-cell-autonomous pathological mechanisms in Parkinson's disease, which are mostly mediated by activated glial and peripheral immune cells. Expand
Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment
TLDR
The dopaminergic basis of the range of non-motor symptoms that occur in PD such as depression, apathy, sleep disorders (including rapid-eye movement sleep behaviour disorder), and erectile dysfunction are investigated. Expand
...
1
2
3
4
5
...